The 36-month beta value for THAR is also noteworthy at 1.51. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for THAR is 1.13M, and at present, short sellers hold a 1.57% of that float. The average trading volume of THAR on October 30, 2024 was 34.65K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
THAR) stock’s latest price update
The stock price of Tharimmune Inc (NASDAQ: THAR) has jumped by 137.85 compared to previous close of 2.03. Despite this, the company has seen a gain of 135.11% in its stock price over the last five trading days. accesswire.com reported 2024-10-30 that BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, received positive feedback from a Scientific Advice meeting with the European Medicines Agency (EMA) that included guidance on a planned Phase 2 trial to advance TH104, the Company’s lead clinical-stage candidate for moderate-to-severe pruritus in primary biliary cholangitis (PBC). The EMA interactions specifically focused on both the Phase 2 and Phase 3 clinical program of TH104.
THAR’s Market Performance
THAR’s stock has risen by 135.11% in the past week, with a monthly rise of 101.18% and a quarterly rise of 49.49%. The volatility ratio for the week is 8.16% while the volatility levels for the last 30 days are 10.48% for Tharimmune Inc The simple moving average for the last 20 days is 117.61% for THAR’s stock, with a simple moving average of 10.19% for the last 200 days.
THAR Trading at 87.96% from the 50-Day Moving Average
After a stumble in the market that brought THAR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.23% of loss for the given period.
Volatility was left at 10.48%, however, over the last 30 days, the volatility rate increased by 8.16%, as shares surge +83.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +55.56% upper at present.
During the last 5 trading sessions, THAR rose by +111.33%, which changed the moving average for the period of 200-days by -31.27% in comparison to the 20-day moving average, which settled at $2.19. In addition, Tharimmune Inc saw -36.76% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at THAR starting from MILBY RANDY, who purchase 2,500 shares at the price of $2.09 back on Oct 08 ’24. After this action, MILBY RANDY now owns 12,934 shares of Tharimmune Inc, valued at $5,221 using the latest closing price.
Appajosyula Sireesh, the Chief Operating Officer of Tharimmune Inc, purchase 5,000 shares at $1.93 during a trade that took place back on Oct 08 ’24, which means that Appajosyula Sireesh is holding 16,364 shares at $9,650 based on the most recent closing price.
Stock Fundamentals for THAR
The total capital return value is set at -1.36. Equity return is now at value -181.81, with -138.06 for asset returns.
Based on Tharimmune Inc (THAR), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -36.64. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -660.78.
Currently, EBITDA for the company is -9.3 million with net debt to EBITDA at 0.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.24.
Conclusion
In summary, Tharimmune Inc (THAR) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
